{"id":"sunitinib-sutent","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Fatigue"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"25-35","effect":"Nausea"},{"rate":"25-30","effect":"Hand-foot skin reaction"},{"rate":"20-30","effect":"Hypertension"},{"rate":"20-25","effect":"Anemia"},{"rate":"15-25","effect":"Thrombocytopenia"},{"rate":"15-20","effect":"Neutropenia"},{"rate":"15-20","effect":"Rash"},{"rate":"10-15","effect":"Hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL535","moleculeType":"Small molecule","molecularWeight":"398.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sunitinib inhibits multiple receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and KIT, which are critical for tumor blood vessel formation and cancer cell survival. By blocking these pathways, it reduces tumor vascularity and directly suppresses cancer cell growth. This dual mechanism of anti-angiogenic and anti-proliferative activity makes it effective against multiple cancer types.","oneSentence":"Sunitinib is a multi-targeted tyrosine kinase inhibitor that blocks growth factor receptors (VEGFR, PDGFR, KIT, FLT3) to inhibit tumor angiogenesis and cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:08.567Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic renal cell carcinoma"},{"name":"Gastrointestinal stromal tumor (GIST)"},{"name":"Pancreatic neuroendocrine tumors"},{"name":"Thyroid cancer (medullary and differentiated)"}]},"trialDetails":[{"nctId":"NCT05687123","phase":"PHASE1","title":"Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-14","conditions":"Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8","enrollment":24},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":"Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":100},{"nctId":"NCT07485569","phase":"PHASE1","title":"Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-06-01","conditions":"Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer, Differentiated Thyroid Cancer","enrollment":10},{"nctId":"NCT01396408","phase":"PHASE2","title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2012-02-09","conditions":"Advanced Rare Tumours","enrollment":137},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT06390826","phase":"PHASE2","title":"Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-11-01","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":10},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT05024214","phase":"PHASE1, PHASE2","title":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","status":"RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","startDate":"2021-11-15","conditions":"Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma","enrollment":170},{"nctId":"NCT06948955","phase":"","title":"Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors","status":"AVAILABLE","sponsor":"Cogent Biosciences, Inc.","startDate":"","conditions":"Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors","enrollment":""},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT06955169","phase":"PHASE2","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","status":"RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2025-12-24","conditions":"Intracranial Meningioma","enrollment":153},{"nctId":"NCT03463460","phase":"PHASE2","title":"Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dwight Owen","startDate":"2018-06-19","conditions":"Thymic Carcinoma","enrollment":9},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT07477457","phase":"PHASE2","title":"A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-11","conditions":"Osteosarcoma, Metastasis","enrollment":45},{"nctId":"NCT02068586","phase":"PHASE2","title":"Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2014-11-19","conditions":"Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma","enrollment":210},{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":554},{"nctId":"NCT02811861","phase":"PHASE3","title":"Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2016-10-13","conditions":"Renal Cell Carcinoma","enrollment":1069},{"nctId":"NCT05381753","phase":"","title":"Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2022-08-29","conditions":"Gastrointestinal Stromal Tumors","enrollment":61},{"nctId":"NCT03673501","phase":"PHASE3","title":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2019-02-08","conditions":"Gastrointestinal Stromal Tumors","enrollment":453},{"nctId":"NCT05208047","phase":"PHASE3","title":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cogent Biosciences, Inc.","startDate":"2022-04-14","conditions":"Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer","enrollment":442},{"nctId":"NCT03900793","phase":"PHASE1","title":"Losartan + Sunitinib in Treatment of Osteosarcoma","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2019-08-26","conditions":"Osteosarcoma","enrollment":41},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":34},{"nctId":"NCT02853331","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-09-16","conditions":"Renal Cell Carcinoma","enrollment":861},{"nctId":"NCT07218926","phase":"PHASE3","title":"A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-12-03","conditions":"Gastrointestinal Neoplasms","enrollment":450},{"nctId":"NCT03768063","phase":"PHASE3","title":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-02-28","conditions":"Cancer","enrollment":1000},{"nctId":"NCT03091192","phase":"PHASE3","title":"Savolitinib vs. Sunitinib in MET-driven PRCC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-07-25","conditions":"Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms","enrollment":60},{"nctId":"NCT05245968","phase":"PHASE1","title":"A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2021-12-01","conditions":"Gastrointestinal Stromal Tumors","enrollment":78},{"nctId":"NCT05477576","phase":"PHASE3","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","status":"RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2022-03-24","conditions":"GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease","enrollment":288},{"nctId":"NCT06726421","phase":"PHASE3","title":"Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-18","conditions":"Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic","enrollment":252},{"nctId":"NCT03541902","phase":"PHASE2","title":"Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-15","conditions":"Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma","enrollment":32},{"nctId":"NCT00329043","phase":"PHASE2","title":"Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-05-15","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT00715442","phase":"PHASE2","title":"Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-06-24","conditions":"Renal Cell Carcinoma","enrollment":50},{"nctId":"NCT05734105","phase":"PHASE3","title":"A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2023-12-13","conditions":"GIST","enrollment":54},{"nctId":"NCT02404584","phase":"","title":"The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2015-12-29","conditions":"Kidney Neoplasms","enrollment":43},{"nctId":"NCT04394975","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-08-20","conditions":"Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1","enrollment":421},{"nctId":"NCT07024680","phase":"","title":"Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-31","conditions":"Papillary Renal Cell Carcinoma","enrollment":150},{"nctId":"NCT05489237","phase":"PHASE1","title":"First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors","status":"RECRUITING","sponsor":"IDRx Inc. - A GSK Company","startDate":"2022-08-03","conditions":"Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease","enrollment":278},{"nctId":"NCT06208748","phase":"PHASE2","title":"SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarcoma Alliance for Research through Collaboration","startDate":"2024-08-01","conditions":"Gastrointestinal Stromal Tumors, GIST","enrollment":40},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT07165418","phase":"PHASE3","title":"A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-09-25","conditions":"Renal Cell Carcinoma (RCC)","enrollment":116},{"nctId":"NCT05366816","phase":"PHASE2","title":"ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-10-17","conditions":"Gastrointestinal Stromal Tumors","enrollment":48},{"nctId":"NCT00930033","phase":"PHASE3","title":"Clinical Trial to Assess the Importance of Nephrectomy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-09-09","conditions":"Metastatic Renal Cell Carcinoma","enrollment":452},{"nctId":"NCT05660954","phase":"PHASE2","title":"Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2023-05-25","conditions":"Differentiated Thyroid Cancer","enrollment":41},{"nctId":"NCT01907607","phase":"PHASE2","title":"Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2014-02","conditions":"Advanced Gastrointestinal Stromal Tumors","enrollment":29},{"nctId":"NCT00265798","phase":"PHASE2","title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-14","conditions":"Gastrointestinal Stromal Tumor","enrollment":38},{"nctId":"NCT01582204","phase":"NA","title":"Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-04","conditions":"Renal Cancer","enrollment":17},{"nctId":"NCT07096609","phase":"PHASE1, PHASE2","title":"Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-09-08","conditions":"GIST","enrollment":48},{"nctId":"NCT02684006","phase":"PHASE3","title":"A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-03-23","conditions":"Renal Cell Cancer","enrollment":886},{"nctId":"NCT03260894","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-12-07","conditions":"Renal Cell Carcinoma (RCC)","enrollment":129},{"nctId":"NCT02533258","phase":"","title":"Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-12-02","conditions":"Renal Cell Carcinoma","enrollment":13},{"nctId":"NCT05678673","phase":"PHASE3","title":"Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2023-01-01","conditions":"Non-Clear Cell Renal Cell Carcinoma","enrollment":317},{"nctId":"NCT01286896","phase":"PHASE1","title":"Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2011-04-11","conditions":"Malignant Solid Tumour","enrollment":43},{"nctId":"NCT02231749","phase":"PHASE3","title":"Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-10-16","conditions":"Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma","enrollment":1390},{"nctId":"NCT03141177","phase":"PHASE3","title":"A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2017-07-23","conditions":"Renal Cell Carcinoma","enrollment":701},{"nctId":"NCT05043090","phase":"PHASE3","title":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-28","conditions":"Papillary Renal Cell Carcinoma","enrollment":148},{"nctId":"NCT00437372","phase":"PHASE1","title":"Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2007-03","conditions":"Cancer, Head and Neck Cancer, Pelvic Cancer","enrollment":39},{"nctId":"NCT06940349","phase":"PHASE1, PHASE2","title":"Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Rabin Medical Center","startDate":"2021-10-21","conditions":"Solid Tumors Refractory to Standard Therapy","enrollment":100},{"nctId":"NCT02230176","phase":"PHASE2","title":"Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2015-02","conditions":"Pancreatic Neuroendocrine Carcinoma","enrollment":84},{"nctId":"NCT05443087","phase":"NA","title":"TARGETed Therapy Drug MONITOring in DIGestive Oncology","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-08-29","conditions":"Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma","enrollment":330},{"nctId":"NCT00720941","phase":"PHASE3","title":"Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-08-14","conditions":"Carcinoma, Renal Cell","enrollment":1110},{"nctId":"NCT01147822","phase":"PHASE2","title":"Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-05-19","conditions":"Carcinoma, Renal Cell","enrollment":367},{"nctId":"NCT00381641","phase":"PHASE2","title":"Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-08-29","conditions":"Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma","enrollment":63},{"nctId":"NCT04659343","phase":"","title":"TDM for Optimized Outcome in Patients With mRCC.","status":"RECRUITING","sponsor":"Niels Fristrup","startDate":"2020-11-01","conditions":"Kidney Cancer, Renal Cell Carcinoma Metastatic, Drug Toxicity","enrollment":200},{"nctId":"NCT06222593","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC","status":"RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2024-10-01","conditions":"Carcinoma, Renal Cell","enrollment":28},{"nctId":"NCT03013946","phase":"PHASE3","title":"Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2017-01-18","conditions":"Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent","enrollment":121},{"nctId":"NCT02401815","phase":"PHASE1, PHASE2","title":"CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cogent Biosciences, Inc.","startDate":"2015-03-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":51},{"nctId":"NCT00961571","phase":"PHASE2","title":"Sunitinib and Capecitabine for First Line Colon Cancer","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2009-08","conditions":"Metastatic Colorectal Cancer","enrollment":50},{"nctId":"NCT04633122","phase":"PHASE2","title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","status":"COMPLETED","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2020-11-25","conditions":"Gastrointestinal Stromal Tumor(GIST)","enrollment":108},{"nctId":"NCT01254864","phase":"PHASE2","title":"Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-03-16","conditions":"Prostate Cancer","enrollment":190},{"nctId":"NCT02761057","phase":"PHASE2","title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-25","conditions":"Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":152},{"nctId":"NCT00843037","phase":"PHASE2","title":"Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2009-02","conditions":"Paraganglioma, Pheochromocytoma","enrollment":25},{"nctId":"NCT04523272","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-08-25","conditions":"Advanced Renal Cancer","enrollment":528},{"nctId":"NCT03109015","phase":"PHASE2","title":"Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-09-27","conditions":"Carcinoma, Renal Cell","enrollment":7},{"nctId":"NCT05363072","phase":"","title":"A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-05-02","conditions":"Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney","enrollment":1112},{"nctId":"NCT01306045","phase":"PHASE2","title":"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-08","conditions":"Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic","enrollment":647},{"nctId":"NCT01621568","phase":"PHASE2","title":"Sunitinib for Advanced Thymus Cancer Following Earlier Treatment","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-15","conditions":"Thymoma, Thymus Neoplasms","enrollment":56},{"nctId":"NCT00700258","phase":"","title":"Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02-13","conditions":"Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors","enrollment":1520},{"nctId":"NCT03277924","phase":"PHASE1, PHASE2","title":"Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas","status":"COMPLETED","sponsor":"Grupo Espanol de Investigacion en Sarcomas","startDate":"2017-05-31","conditions":"Soft Tissue Sarcoma, Bone Sarcoma","enrollment":197},{"nctId":"NCT05745142","phase":"","title":"A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-23","conditions":"Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma","enrollment":376},{"nctId":"NCT04669366","phase":"","title":"Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-01-20","conditions":"Kidney Neoplasms","enrollment":1205},{"nctId":"NCT00330564","phase":"PHASE2","title":"Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-05","conditions":"Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma","enrollment":15},{"nctId":"NCT03905889","phase":"PHASE1","title":"A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma","status":"TERMINATED","sponsor":"Brown University","startDate":"2019-06-05","conditions":"Renal Cell Carcinoma Metastatic","enrollment":3},{"nctId":"NCT02282059","phase":"","title":"The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-12-12","conditions":"Pancreatic Neuroendocrine Tumors","enrollment":100},{"nctId":"NCT06326346","phase":"PHASE2","title":"GIST Oral Paclitaxel(Liporaxel)","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2024-08-01","conditions":"Gastrointestinal Stromal Tumors","enrollment":28},{"nctId":"NCT04893785","phase":"PHASE2","title":"A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2021-06-15","conditions":"Lung Neuroendocrine Neoplasm, GEP Neuroendocrine Tumor","enrollment":35},{"nctId":"NCT04193553","phase":"PHASE2","title":"Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2020-01-17","conditions":"Gastro Intestinal Stromal Tumour","enrollment":77},{"nctId":"NCT05160168","phase":"PHASE1, PHASE2","title":"A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","status":"TERMINATED","sponsor":"Theseus Pharmaceuticals","startDate":"2022-01-03","conditions":"Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue","enrollment":32},{"nctId":"NCT06427057","phase":"PHASE2","title":"A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-07-01","conditions":"Urinary System Tumor","enrollment":40},{"nctId":"NCT03140176","phase":"","title":"Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2017-08-15","conditions":"Metastatic Renal Cell Carcinoma","enrollment":77},{"nctId":"NCT00831857","phase":"","title":"VEGF Imaging in Renal Cell Carcinoma","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2009-01","conditions":"Renal Cell Carcinoma","enrollment":26},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT05905887","phase":"PHASE2","title":"Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2023-09-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":48},{"nctId":"NCT00482755","phase":"PHASE2","title":"Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2009-04-08","conditions":"Breast Cancer","enrollment":4},{"nctId":"NCT04409223","phase":"PHASE3","title":"Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-12","conditions":"Gastrointestinal Stromal Tumors","enrollment":185},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT00673816","phase":"PHASE1, PHASE2","title":"Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome","status":"TERMINATED","sponsor":"National Eye Institute (NEI)","startDate":"2008-05","conditions":"Von Hippel-Lindau Syndrome","enrollment":2},{"nctId":"NCT03944304","phase":"PHASE2","title":"Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2019-05-27","conditions":"Gastrointestinal Stromal Tumors","enrollment":40},{"nctId":"NCT05949424","phase":"PHASE4","title":"OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2024-05","conditions":"Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma","enrollment":30},{"nctId":"NCT02483247","phase":"PHASE1","title":"A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2015-09","conditions":"Cancer","enrollment":165},{"nctId":"NCT01934452","phase":"","title":"Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-05-21","conditions":"Complete Remission in Renal Cell Carcinoma","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sutent"],"phase":"marketed","status":"active","brandName":"Sunitinib (Sutent)","genericName":"Sunitinib (Sutent)","companyName":"Sponsor GmbH","companyId":"sponsor-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sunitinib is a multi-targeted tyrosine kinase inhibitor that blocks growth factor receptors (VEGFR, PDGFR, KIT, FLT3) to inhibit tumor angiogenesis and cell proliferation. Used for Metastatic renal cell carcinoma, Gastrointestinal stromal tumor (GIST), Pancreatic neuroendocrine tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}